1. Home
  2. SXI vs IBRX Comparison

SXI vs IBRX Comparison

Compare SXI & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SXI
  • IBRX
  • Stock Information
  • Founded
  • SXI 1955
  • IBRX 2014
  • Country
  • SXI United States
  • IBRX United States
  • Employees
  • SXI N/A
  • IBRX N/A
  • Industry
  • SXI Industrial Machinery/Components
  • IBRX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SXI Industrials
  • IBRX Health Care
  • Exchange
  • SXI Nasdaq
  • IBRX Nasdaq
  • Market Cap
  • SXI 2.6B
  • IBRX 2.3B
  • IPO Year
  • SXI N/A
  • IBRX N/A
  • Fundamental
  • Price
  • SXI $218.47
  • IBRX $2.44
  • Analyst Decision
  • SXI Strong Buy
  • IBRX Strong Buy
  • Analyst Count
  • SXI 4
  • IBRX 6
  • Target Price
  • SXI $223.50
  • IBRX $9.83
  • AVG Volume (30 Days)
  • SXI 102.8K
  • IBRX 10.2M
  • Earning Date
  • SXI 10-28-2025
  • IBRX 11-11-2025
  • Dividend Yield
  • SXI 0.60%
  • IBRX N/A
  • EPS Growth
  • SXI N/A
  • IBRX N/A
  • EPS
  • SXI 4.64
  • IBRX N/A
  • Revenue
  • SXI $790,107,000.00
  • IBRX $56,600,000.00
  • Revenue This Year
  • SXI $14.61
  • IBRX $629.94
  • Revenue Next Year
  • SXI $7.59
  • IBRX $109.91
  • P/E Ratio
  • SXI $45.97
  • IBRX N/A
  • Revenue Growth
  • SXI 9.64
  • IBRX 4227.22
  • 52 Week Low
  • SXI $128.85
  • IBRX $1.83
  • 52 Week High
  • SXI $219.28
  • IBRX $7.48
  • Technical
  • Relative Strength Index (RSI)
  • SXI 61.91
  • IBRX 43.22
  • Support Level
  • SXI $209.85
  • IBRX $2.45
  • Resistance Level
  • SXI $219.83
  • IBRX $2.61
  • Average True Range (ATR)
  • SXI 5.02
  • IBRX 0.12
  • MACD
  • SXI 0.63
  • IBRX -0.01
  • Stochastic Oscillator
  • SXI 93.21
  • IBRX 17.57

About SXI Standex International Corporation

Standex International Corp is an industrial manufacturer of different products and services used in commercial and industrial markets. The company has five reportable segments: Electronics, Engraving, Scientific, Engineering Technologies, and Specialty Solutions. The maximum revenue is generated from its Electronics segment, which is a component and value-added services provider of both sensing and switching technologies, as well as magnetic power conversion components and assemblies, like custom wound transformers and inductors, current sense technology, value-added assemblies, and mechanical packaging, among others. Geographically, it derives key revenue from the United States and the rest from the Asia Pacific, Europe, the Middle East, and Africa (EMEA), as well as other regions.

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

Share on Social Networks: